Plain-English translation of NCT06736613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is studying a new way to detect cancer cells in spinal fluid that might predict whether aggressive B-cell lymphoma will come back in the brain. Researchers want to see if this test can catch warning signs earlier than standard methods, before symptoms appear. The study will help doctors understand who needs extra protection or closer monitoring during treatment.
Many patients with aggressive B-cell lymphoma face a serious risk that their cancer will return in the brain or nervous system, which is hard to catch and treat. This new test could help doctors identify high-risk patients sooner and decide on better prevention strategies, potentially saving lives.
You likely qualify if…
You likely don't qualify if…
You will have a lumbar puncture (spinal tap) performed to collect spinal fluid for testing, which will happen as part of your standard cancer workup before or during treatment. The study team will monitor you over time to see whether the test result predicts whether your cancer comes back in the brain. You'll continue your regular chemotherapy treatment, and the researchers will follow your progress to compare outcomes between patients with and without this warning marker in their spinal fluid.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States